Introduction {#sec1}
============

*Haemophilus influenzae* is a commensal bacterium of the human upper respiratory tract, oropharynx and nasopharynx. It is one of the most frequent pathogens responsible for bronchopulmonary, ear, nose and throat infections \[[@bib1]\]. Also, it represents the principal aetiology of invasive infections such as purulent meningitis, bacteraemia and epiglottitis mainly in infants \[[@bib1]\]. β-Lactams, mainly third-generation cephalosporins, are active against *H. influenzae*. However, the emergence and spread of resistant strains worldwide can severely affect their efficacy \[[@bib2]\]. Resistance to β-lactams in *H. influenzae* is predominantly mediated by TEM-1 or ROB-1 β-lactamase production and is associated with resistance to aminopenicillins, of which the activity spectrum is limited to penicillins. Strains producing β-lactamases are termed β-lactamase-positive ampicillin-resistant. The second mechanism of resistance is non-enzymatic, due to decreased affinity of β-lactams for the altered transpeptidase domain of penicillin-binding protein 3 (PBP3), involved in septal peptidoglycan synthesis and encoded by the *ftsI* gene \[[@bib1]\]. Strains expressing this mechanism are termed β-lactamase-negative ampicillin-resistant (BLNAR). Resistance by the latter mechanism can affect penicillins, penicillin and penicillinase inhibitor associations, cephalosporins and carbapenems, depending on the number and the type of mutations in the *ftsI* gene \[[@bib1]\]. Strains that accumulate the two mechanisms are termed β-lactamase-positive clavulanic-acid-resistant (BLPCAR) \[[@bib1]\]. In BLNAR strains, amino acid substitutions are usually surrounding the conserved motifs Lys512-Thr-Gly (KTG) and Ser379-Ser-Asn (SSN) of the PBP3 transpeptidase domain. More than 40 substitutions have been described in the literature and it has been found that a single BLNAR isolate could accumulate from one to 11 substitutions \[[@bib1]\]. According to specific substitutions, BLNAR isolates have been classified into four major mutational groups (I, II, III and III-like). In group I, His-517 was substituted by Arg and in group II Lys-526 was substituted by Asn. Ampicillin MICs of these groups varied between 0.5 and 8 mg/L and they are considered low BLNAR. Group III and group III-like were defined by the second substitution S385T in addition to the first one N526K or R517H, respectively. They present full resistance to ampicillin (MIC range 1--32 mg/L) and cephalosporins (MIC range 0.12--2 mg/L) and considered high BLNAR \[[@bib3],[@bib4]\]. Furthermore, isolates from group III and group--III--like with the additional substitution L389F showed generally higher MICs to extended-spectrum cephalosporins and meropenem. Hence, two new groups---III+ and group--III--like+---have been proposed by Skaare et al. for these strains \[[@bib2]\]. In *H. influenzae* enzymatic resistance has historically predominated, with a prevalence \>20% in many European countries, Australia and Canada. Recent studies showed that the prevalence of β-lactamase-positive ampicillin-resistant strains is stabilizing or decreasing. By contrast, a significant increase of BLNAR phenotype was observed in these same countries \[[@bib1]\]. The situation in Japan is different and usually marked by high prevalence of BLNAR strains. In addition, high BLNAR strains have been rarely reported outside Asian countries, particularly Japan and Korea \[[@bib5]\].

In Tunisia, multicentric studies on antimicrobial resistance of *H. influenzae* showed that β-lactamase production was the most common mechanism of resistance to β-lactams during all years of surveillance (1999--2017). The prevalence of β-lactamase-positive ampicillin-resistant strains varied from 17.3% in 1999 to 36.6% in 2017. BLNAR isolates emerged in 2006 at low frequencies with significant increase from 2.9% in 2007 to 8.2% in 2017 ([www.infectiologie.org.tn](http://www.infectiologie.org.tn){#intref0010}). In Tunisia, BLNAR strains are routinely detected by phenotypic methods and few data are available on the genetic classification of their *ftsI* gene. Accordingly, we aimed to characterize the polymorphism of *ftsI* gene in a Tunisian collection of 19 *H. influenzae* strains, isolated between 2014 and 2016, and to assess the clonality among them.

Materials and methods {#sec2}
=====================

Strain collection {#sec2.1}
-----------------

*Haemophilus influenzae* isolates included in the study were distributed as follows:•Seven strains recovered from the microbial Laboratory of Charles Nicolle Hospital, including three low BLNAR isolates (β-lactamase-negative, ampicillin MIC \>1 mg/L) and four BLPCAR isolates (ampicillin/clavulanic acid MIC \>2 mg/L).•Two cefotaxime-resistant *H. influenzae* strains (Hi16 and Hi19) isolated at the microbiology laboratories of the Charles Nicolle (Tunis city) and Abderrahman Mami (Ariana city) hospitals, respectively.•Ten control isolates, fully susceptible to β-lactams: β-lactamase-negative ampicillin-susceptible strains, randomly selected, used for comparative purposes.

Strain identification {#sec2.2}
---------------------

Isolates were identified through Gram-staining that usually showed a pleomorphic Gram-negative bacilli, their requirements for β-NAD^+^ (V factor) and haemin (X factor) for growth and by API NH (bioMérieux, Marcy-l'Étoile, France). Chocolate agar plates (bioMérieux) were routinely used for subcultures of *H*. *influenzae*. Biotypes were determined using indole, urease and ornithine decarboxylase reactions revealed by API NH \[[@bib6]\].

Antimicrobial susceptibility testing {#sec2.3}
------------------------------------

Antimicrobial susceptibility was determined by disc diffusion method, according to the European Committee on Antimicrobial Susceptibility Testing recommendations (CA-SFM/EUCAST) \[[@bib7]\]. The antibiotics tested were penicillin G (1 μg), ampicillin (2 μg), amoxicillin/clavulanic acid (2 μg/1 μg), cefotaxime (5 μg), nalidixic acid (30 μg), ciprofloxacin (5 μg), tetracycline (30 μg), chloramphenicol (30 μg), rifampicin (5 μg) and trimethoprim-sulfamethoxazole (1.25--23.75 μg). β-Lactamase production was determined by the chromogenic cephalosporin test (cefinase test) with nitrocefin as the substrate (bioMérieux). MICs of ampicillin, amoxicillin/clavulanic acid and cefotaxime were determined by E-test strips (bioMérieux) and were interpreted according to the EUCAST breakpoints.

Amplification and sequencing of ftsI gene {#sec2.4}
-----------------------------------------

Mutations in *ftsI* gene encoding PBP3 were identified by PCR and sequencing as previously described \[[@bib8]\].

β-lactamases gene detection {#sec2.5}
---------------------------

*Haemophilus influenzae* strains with BLPCAR phenotype were screened for *bla*~*TEM*~ and *bla*~*ROB*~ genes using multiplex PCR as previously described \[[@bib9]\].

Capsular typing and genetic relationship {#sec2.6}
----------------------------------------

Capsular type was identified by slide agglutination using specific anti-sera (Difco, BD, Le Pont de Claix, France) and was confirmed by PCR \[[@bib10]\]. The *H. influenzae* ATCC 10211 (strain with capsular type b was used as a positive control.

The genetic relationship between isolates was analysed by pulsed-field gel electrophoresis (PFGE). The PFGE Pulse Net protocol of *Escherichia coli* was adapted to *H. influenzae* strains using *Sma*I restriction enzyme (New England BioLabs, Ipswich, MA, USA; <https://www.cdc.gov/pulsenet/pathogens/pfge.html>). DNA profiles were examined with FP-Quest software (BioRad, Marnes la Coquette, France) and using the Dice coefficient and UPGMA (unweighted pair group method with arithmetic mean). Clusters were defined as DNA patterns sharing ≥70% similarity, which corresponds to the possibly related criteria of Tenover et al. \[[@bib11]\].

Results {#sec3}
=======

Clinical data {#sec3.1}
-------------

Demographic and clinical data of patients are summarized in [Table 1](#tbl1){ref-type="table"}. Most *H. influenzae* strains were isolated from sputum (*n* = 15). They were mainly recovered from pneumology (*n* = 5), otorhinolaryngology (*n* = 3) and paediatrics (*n* = 3) wards. Fifteen (78.9%) infections were classified as community-acquired ([Table 1](#tbl1){ref-type="table"}).Table 1Clinical characteristics and biotype of *Haemophilus influenzae* strains (*n* = 19)Table 1Reference strainsDate of isolationPatient age/GenderSpecimensWardsInfection originBiotypeβ-lactam-susceptible strains (Control group)Hi 218/07/201479 years/FBronchial secretionIntensive care unitCAIHi 311/03/2015--/FSputumExternal consultationCAIVHi 512/05/2015--/MSputumPneumologyCAIVHi 601/06/201581 years/MBronchial secretionIntensive care unitHAIVHi 710/07/2015--/FSputumPneumologyCAIHi 828/07/2015--/MBronchial secretionPneumologyCAIHi 912/08/201575 years/MBronchial secretionSurgeryHAIVHi 1112/09/201514 years/MSputumPaediatricsCAIHi 1230/10/2015--/FSputumPaediatricsCAIHi 1311/11/201514 years/FPusOtorhinolaryngologyCAIβ-lactam-resistant strainsHi 117/07/201455 years/FSputumOtorhinolaryngologyCAIHi 410/04/2015--/FSputumPneumologyCAIIHi 1023/09/20159 years/FSputumPaediatricsCAVIIIHi 1430/10/2015--/FSputumPneumologyCAIHi 1530/12/20151 year/MPusForensicMedicineCAIVHi 1620/01/201662 years/MSputumGastroenterologyHAIVHi 1705/03/2016--/MPusOtorhinolaryngologyCAIVHi 1811/03/2016--/FSputumPaediatricsCAIVHi 19[a](#tbl1fna){ref-type="table-fn"}30/08/201672 years/MSputumThoracic surgeryHAIV[^1][^2]

For the two *H. influenzae* strains resistant to cefotaxime (Hi16 and Hi19) and given the importance of this novel resistance, detailed clinical histories of patients are given below.

Clinical observation no. 1 {#sec3.2}
--------------------------

Hi16 was recovered from a 61-year-old man hospitalized in the gastroenterology ward for decompensated cirrhosis post-viral hepatitis C. Two weeks previously, he was treated with cefotaxime (4 g/day for 15 days) for bacteraemia caused by *E. coli*. Four days after having completed his course of antimicrobial therapy, his clinical state deteriorated and he developed stage II encephalopathy, with dyspnoea and recurrence of fever. An infectious investigation was conducted including chest X-ray, which revealed diffuse alveolar images. Sputum and urine cultures were positive for *H. influenzae* resistant to cefotaxime and *Enterococcus faecium* resistant to glycopeptides, respectively. The patient was treated with ofloxacin (800 mg/day) for 10 days, with clinical and biological improvement.

Clinical observation no. 2 {#sec3.3}
--------------------------

Hi19 was isolated from a 72-year-old man hospitalized in thoracic surgery for acute coronary syndrome. He was a former smoker and was previously hospitalized for acute exacerbation of his chronic obstructive pulmonary disease in 2006 and in 2015. The patient did not receive antibiotics in the previous 6 months. For the current episode, an infectious investigation, including sputum and urine cultures was carried out. The two specimens were positive for *H. influenzae* resistant to cefotaxime and *E. coli*, respectively. The patient was treated with a high dose of cefotaxime (6 g/day) for 10 days and with ciprofloxacin (1500 mg/day) on discharge.

Strain characterization {#sec3.4}
-----------------------

The *H. influenzae* strains were classified into four biotypes. Biotypes IV and I were identified in nine and eight strains, respectively. Susceptible isolates belonged mainly to biotype I (60%), whereas 55.5% of resistant isolates belonged to biotype IV. Biotypes II and VIII were identified in two strains each ([Table 1](#tbl1){ref-type="table"}).

All strains were non-typeable by slide agglutination as well as by PCR amplification. PFGE analysis of *H. influenzae* isolates showed 19 unrelated pulsotypes ([Fig. 1](#fig1){ref-type="fig"}). They were susceptible to nalidixic acid, chloramphenicol and rifampicin, Eight and three strains were resistant to tetracycline and cotrimoxazole, respectively. All four β-lactamase-producing isolates harboured *bla*~TEM-1~ gene ([Table 2](#tbl2){ref-type="table"}).Fig. 1Dendrogram of pulsed-field gel electrophoresis DNA patterns of *Haemophilus influenzae* strains obtained after the UPGMA analysis of the Dice\'s coefficient. BLNAS, β-lactamase-negative ampicillin-susceptible; BLNAR, β-lactamase-negative ampicillin-resistant; BLPCAR, β-lactamase-positive clavulanic-acid-resistant).Fig. 1Table 2Antimicrobial resistance profiles and deduced amino acid substitution patterns in the transpeptidase region of penicillin-binding protein 3 (PBP3) of *Haemophilus influenzae* strainsTable 2Reference StrainsResistance profileCefinase/*bla* genesMICsftsI groupaMutations in ftsI geneAMPAMCCTXD350S357M377S385L389P392N422G490A502V511R517N526S532F535V547I549Y557N569Hi 3------0.250.250.012NAHi 7------0.250.380.016Hi 9TET---0.380.250.012Hi 12TET---0.190.1250.023Hi 13------0.250.1250.016PHi 11TET---0.1250.1250.016IHi 8SXT---0.250.250.012IHi 6------0.750.250.047IHi 5TET---0.50.380.08sIHi 2------0.250.250.016FHi 14AMX-TET---20.1250.064Group IHHi 1AMX---40.1250.023AHHi 10AMX-TET---40.380.023AHHi 17^a^AMX-AMC-SXT+/*bla*~TEM-1~\>25620.064Group IIbNIVKIHi 18 ^a^AMX-AMC+/*bla*~TEM-1~\>25640.047Group IibNIEVKHi 4 ^a^AMX-AMC-TET-SXT+/*bla*~TEM-1~\>25620.047Group IibNIEVKIHi 15^b^AMX-AMC+/*bla*~TEM-1~\>25620.032Group IINII∗VKHi 19AMX-AMC-CTX+/*bla*~TEM-1~\>256\>2561Group--III--like+NNITFHTIHSHi 16AMX-AMC-CTX-TET---2440.5Group III+NNITFTK[^3][^4]

ftsI genotypes and correlation with β-lactam MICs {#sec3.5}
-------------------------------------------------

Sequence analysis of the transpeptidase region of PBP3 showed a total of 19 substitutions in 18 positions. The most frequent mutations were (D350N), (S357I), (R517H) and (N526K). In the Hi15 BLPCAR isolate, a new mutation was observed at position 422 (N422I). For this strain, MICs of ampicillin, amoxicillin/clavulanic acid and cefotaxime were \>256, 2 and 0.032 mg/L, respectively.

Among strains with a β-lactamase-negative ampicillin-susceptible phenotype (control group), four did not harbour mutations in the *ftsI* gene and six displayed different point mutations ([Table 2](#tbl2){ref-type="table"}). Ampicillin MICs varied from 0.19 to 0.75 mg/L (MIC~50~ 0.25 mg/L).

According to the mutation profile of their *ftsI* gene, strains with BLNAR phenotype (*n* = 4) were classified as group I (*n* = 3) and group III+ (*n* = 1) and those with BLPCAR phenotype (*n* = 5) were classified as group II (*n* = 4) and group--III--like (*n* = 1) ([Table 2](#tbl2){ref-type="table"}). Three strains (Hi4, Hi17 and Hi18) from group II were further assigned to subgroup II-b, and were also TEM-1 β-lactamase producers. The remaining strain (Hi15) that had a new mutation (N422I) could not be assigned to any of the previously described group II subgroups. Ampicillin MICs varied between 2 and 4 mg/L in group I and was \>256 mg/L in group II.

Resistance to cefotaxime in strains Hi16 and Hi19 was associated with S385T and L389F mutations, respectively. Strain Hi19 was also a TEM-1 producer. Cefotaxime MICs were 0.5 mg/L and 1 mg/L for Hi16strain (group III+) and Hi19 strain (group III like+), respectively.

High resistance level of ampicillin (\>256 mg/L) was associated with TEM-1 production whatever the *ftsI* mutational resistance group. ROB enzyme has not been found in our collection.

Discussion {#sec4}
==========

In this study, molecular mechanisms of resistance to β-lactams in clinical *H. influenzae* isolates showing different β-lactam resistance phenotypes were investigated. All strains were non-typeable by slide agglutination as well as by PCR amplification. The predominance of non-typeable strains was also reported in other Tunisian studies, and in Korea, Spain and France \[[@bib12],[@bib13]\]. However, previous reports demonstrated the limitation of slide agglutination for *H. influenzae* serotyping in comparison with the results provided by PCR \[[@bib14],[@bib15]\]. This may be related to the individual characteristics of expression of capsule and/or other antigens on the bacterial surface \[[@bib16],[@bib17]\].

In Tunisia, until 2002, all invasive infections in young children were caused by *H. influenzae* b strains \[[@bib18]\], justifying the introduction of the anti-Hib conjugate vaccine. However, given its high cost, it was abandoned at the beginning of 2006. Then, based on extensive evidence demonstrating the economic impact of the anti-Hib conjugate vaccine through direct and indirect cost savings, as well as through contributions to the Tunisian economy in general, this vaccine was reintroduced into the vaccination schedule in 2011 \[[@bib19]\].

In the present study, PFGE analysis of the *H. influenzae* isolates showed diverse pulsotypes, which is in agreement with the genetic heterogeneity of non-capsulated *H. influenzae* previously reported \[[@bib1]\]. Also, according to resistance phenotype, many studies have shown that BLNAR and BLPCAR strains of *H. influenzae* are genetically diverse with a general absence of related PFGE DNA profiles \[[@bib1]\]. Otherwise, clonal spread of BLNAR strains of serotype b was reported by a limited number of studies in Japan \[[@bib20],[@bib21]\]. In comparison, some local outbreaks caused by BLNAR *H. influenzae* strains have been reported, in Norway, Spain and Canada. of BLNAR *H. influenzae* strains that were caused by closely related clones \[[@bib4],[@bib8],[@bib22]\].

Among the β-lactamase-negative ampicillin-susceptible phenotypes (*n* = 10), four strains of our collection had the prototype amino acid sequence of the transpeptidase region of PBP3. In the remaining six strains, different point mutations were found. These observations were previously reported \[[@bib2],[@bib8],[@bib23]\]. Many silent mutations have been reported in the DNA region encoding the transpeptidase domain of PBP3 in susceptible strains \[[@bib23]\]. The results of García-Cobos et al. showed that β-lactams susceptible *H. parainfluenzae* strains presented various substitutions not previously assigned to any *ftsI*-resistant groups \[[@bib4]\].

According to mutational profiles of *ftsI* genes, BLNAR and BLPCAR isolates of our collection were classified as group I, II, IIb, III-like+ and III+. Strain Hi15 belonging to group II, but not assigned to any group II subgroups, showed a new mutation (N422I) in its *ftsI* gene, suggesting a novel subgroup II. The β-lactam resistance in *H. influenzae* due to *ftsI* mutations is increasing worldwide \[[@bib22]\]. Low-level resistance isolates, mainly with the N526K substitutions, predominated in most geographical regions, whereas high-level resistance isolates with additional L389F substitution (ampicillin MIC~50~: 128 mg/L and cephalosporins MIC~50~: 1 mg/L) are common in Japan and South Korea. Epidemiological data from European countries and Canada showed a gradual increase in resistant isolates from group II with sporadic cases of cefotaxime-resistant strains \[[@bib1],[@bib13],[@bib22],[@bib24],[@bib25]\].

In Tunisia, resistance to cefotaxime has been recently reported among six *H. influenzae* isolates from Habib Bourguiba hospital. These strains belonged to group IIa, group IIb, group III and group--III--like \[[@bib26]\]. The two cefotaxime-resistant strains described in our study belonged to group III+ and group--III--like+. According to clinical data, *H. influenzae*-resistant strains were isolated from two elderly individuals with severe underlying diseases, chronic cirrhosis in one and chronic obstructive pulmonary disease in the other. It has been demonstrated that people suffering from chronic obstructive pulmonary disease are frequently colonized by *H. influenzae* in their respiratory tract \[[@bib12],[@bib27]\]. In addition, previous antimicrobial treatment by cefotaxime and iterative hospitalizations are contributing factors for selection of such resistant strains. According to Dabernat et al., the inappropriate use of oral antibiotics for the treatment of community-acquired bronchopulmonary and upper respiratory tract infections seems to be responsible for the selection of BLNAR strains \[[@bib3]\].

In our series, the five BLPCAR isolates harboured the *bla*~TEM-1~ gene. This finding is in agreement with previous Tunisian studies \[[@bib28],[@bib29]\]. Although the predominance of TEM-1 β-lactamase was largely reported worldwide, ROB-1 is rarely found outside North America \[[@bib1]\].

Our study presents two major limitations. First, clinical data were collected retrospectively and detailed information for all patients, such as age, co-morbidities, severity of diseases, antimicrobial treatment history and clinical outcomes could not be obtained. Second, our results gave limited data on the distribution of the *ftsI* group in our country because of the low number of studied strains. Further large studies including other hospital centres will be necessary to assess the real clinical impact of this emerging resistance and to identify additional risk factors for selection of resistant strains.

In conclusion, this study revealed the diversity of mutation profiles in *ftsI* gene among BLNAR and BLPCAR *H. influenzae* strains. Our results further indicate that these strains were non-capsulated and were genetically unrelated. The emergence of strains resistant to extended spectrum β-lactams is alarming and requires strict epidemiological surveillance. Furthermore, rationalization and strict control of antibiotic use, mainly in the community, is needed to preserve the activity of these molecules.
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[^1]: CA, community-acquired infections were defined as infections in which the onset of patient symptoms occurred before admission or within 48 h of admission to the hospital; HA, hospital-acquired infections were defined as infections in which the onset of symptoms occurred more than 48 h after admission.

[^2]: Isolate from Abdurrahman Mami hospital.

[^3]: AMC, ampicillin/clavulanic acid; AMP, ampicillin, CTX, cefotaxime.

[^4]: ^a^ Classification according to Ubukata et al. \[[@bib30]\] (Group I, II and III), Dabernat et al. \[[@bib3]\] (Subgroup II: IIa, IIb, IIc and IId), García-Cobos et al. \[[@bib4]\] (Group--III--like), Skaare et al. \[[@bib23]\] (Group III+ and Group--III--like+): --, negative; NA, non-assigned resistance group, ∗, new mutation.
